Industry: Life Sciences Region: Sweden Transaction Price: US $1million Transaction Method: Equity investment
Investment Advantages:
The company is committed to translating cancer antibody biology into innovative immunooncology therapies.
The company is expanding and developing an exciting line of innovative immunooncology therapies based on its unique F.I.R.S.T™ technology platform and N-Coder ® antibody library.
Traditional chemotherapy methods target tumor cells directly, but are not specific, so they can kill normal cells and cause serious side effects.
The company is developing drugs that activate vital cells in the immune system, particularly T cells, and stimulate them to attack tumor cells.
Cooperation Intention:
The company is now looking for a Chinese research and development partner.